EMERYVILLE, Calif., Oct. 02, 2020 (GLOBE NEWSWIRE) — Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, and its subsidiary Modis Therapeutics, shared new data and information about MT1621, the company’s investigational therapy for Thymidine kinase 2 deficiency (TK2d), at this week’s International Congress […]
Click here to view original web page at www.globenewswire.com